Lyell Immunopharma, Inc.
LYEL
$9.69
$0.262.76%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -46.50% | -46.18% | -7.31% | -0.36% | -25.51% |
| Total Depreciation and Amortization | -10.86% | -3.06% | -2.83% | 1.70% | 7.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 241.94% | 247.15% | -37.86% | -54.19% | -44.24% |
| Change in Net Operating Assets | -309.94% | -191.20% | 96.57% | 99.90% | 105.36% |
| Cash from Operations | -9.79% | 0.79% | 4.62% | 2.65% | 5.01% |
| Capital Expenditure | 42.52% | 82.73% | 93.86% | 94.09% | 92.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.34% | -17.40% | -109.25% | -63.92% | 178.72% |
| Cash from Investing | -2.30% | -33.48% | -109.59% | -62.22% | 272.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -43.60% | -36.27% | -18.81% | -73.82% | -73.04% |
| Repurchase of Common Stock | 100.00% | 83.37% | 53.50% | 28.62% | 12.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -29.31% | -23.92% | -10.77% | -77.70% | -77.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -124.15% | -274.88% | -209.42% | -588.00% | 114.34% |